Metabolic Scar Assessment with<sup>18</sup>F-FDG PET: Correlation to Ischemic Ventricular Tachycardia Substrate and Successful Ablation Sites.

Ghzally, Yousra; Imanli, Hasan; Smith, Mark; Mahat, Jagat; Chen, Wengen; Jimenez, Alejandro; Sawan, Mariem A; Abdelmegid, Mohamed Aboel-Kassem F et al. · J Nucl Med · 2021

Where this comes from

Abstract

The functional and molecular imaging characteristics of ischemic ventricular tachycardia (VT) substrate are incompletely understood. Our objective was to compare regional <sup>18</sup>F-FDG PET tracer uptake with detailed electroanatomic maps (EAMs) in a more extensive series of postinfarction VT patients to define the metabolic properties of VT substrate and successful ablation sites. <b>Methods:</b> Three-dimensional (3D) metabolic left ventricular reconstructions were created from perfusion-normalized <sup>18</sup>F-FDG PET images in consecutive patients undergoing VT ablation. PET defects were classified as severe (defined as <50% uptake) or moderate (defined as 50%-70% uptake), as referenced to the maximal 17-segment uptake. Color-coded PET scar reconstructions were coregistered with corresponding high-resolution 3D EAMs, which were classified as indicating dense scarring (defined as voltage < 0.5 mV), normal myocardium (defined as voltage > 1.5 mV), or border zones (defined as voltage of 0.5-1.5 mV). <b>Results:</b> All 56 patients had ischemic cardiomyopathy (ejection fraction, 29% ± 12%). Severe PET defects were larger than dense scarring, at 63.0 ± 48.4 cm<sup>2</sup> versus 13.8 ± 33.1 cm<sup>2</sup> (<i>P</i> < 0.001). Similarly, moderate/severe PET defects (≤70%) were larger than areas with abnormal voltage (≤1.5 mV) measuring 105.1 ± 67.2 cm<sup>2</sup> versus 56.2 ± 62.6 cm<sup>2</sup> (<i>P</i> < 0.001). Analysis of bipolar voltage (23,389 mapping points) showed decreased voltage among severe PET defects (<i>n</i> = 10,364; 0.5 ± 0.3 mV) and moderate PET defects (<i>n</i> = 5,243; 1.5 ± 0.9 mV, <i>P</i> < 0.01), with normal voltage among normal PET areas (>70% uptake) (<i>n</i> = 7,782, 3.2 ± 1.3 mV, <i>P</i> < 0.001). Eighty-eight percent of VT channel or exit sites (<i>n</i> = 44) were metabolically abnormal (severe PET defect, 78%; moderate PET defect, 10%), whereas 12% (<i>n</i> = 6) were in PET-normal areas. Metabolic channels (<i>n</i> = 26) existed in 45% (<i>n</i> = 25) of patients, with an average length and width of 17.6 ± 12.5 mm and 10.3 ± 4.2 mm, respectively. Metabolic channels were oriented predominantly in the apex or base (86%), harboring VT channel or exit sites in 31%. Metabolic rapid-transition areas (>50% change in <sup>18</sup>F-FDG tracer uptake/15 mm) were detected in 59% of cases (<i>n</i> = 33), colocalizing to VT channels or exit sites (15%) or near these sites (85%, 12.8 ± 8.5 mm). Metabolism-voltage mismatches in which there was a severe PET defect but voltage indicating normal myocardium were seen in 21% of patients (<i>n</i> = 12), 41% of whom were harboring VT channel or exit sites. <b>Conclusion:</b> Abnormal <sup>18</sup>F-FDG uptake categories could be detected using incremental 3D step-up reconstructions. They predicted decreasing bipolar voltages and VT channel or exit sites in about 90% of cases. Additionally, functional imaging allowed detection of novel molecular tissue characteristics within the ischemic VT substrate such as metabolic channels, rapid-transition areas, and metabolism-voltage mismatches demonstrating intrasubstrate heterogeneity and providing possible targets for imaging-guided ablation.

Medical subject headings